Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and Cisplatin for Re-Irradiation of Head and Neck Cancer
NCT02158234Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2014
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cisplatin in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Moffitt Cancer Center. Primary endpoint: Maximal Tolerated Dose of Stereotactic Body Radiation Therapy up to 24 months. Started Jul 2014; status: completed.
02
Drugs
cisplatin
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02158234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02158234.